Selling, General, and Administrative Costs: Amgen Inc. vs Sanofi

A Comparative Analysis of SG&A Expenses: Amgen Inc. vs. Sanofi

In the competitive landscape of the pharmaceutical industry, managing operational costs is crucial for maintaining profitability. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry giants, Amgen Inc. and Sanofi, from 2014 to 2023. Over this period, Sanofi consistently outspent Amgen, with SG&A costs averaging around 9.8 billion USD annually, compared to Amgen's 5.3 billion USD. Notably, Sanofi's expenses peaked in 2023, reaching approximately 10.8 billion USD, marking a 26% increase from 2014. Meanwhile, Amgen's expenses saw a 31% rise, culminating in 6.2 billion USD in 2023. This trend highlights the strategic investments both companies are making in marketing and administrative functions to bolster their market positions. Understanding these financial dynamics offers valuable insights into the operational strategies of leading pharmaceutical firms.